PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
AIDS Res Hum Retroviruses. Jan 2011; 27(1): 35–39.
PMCID: PMC3034096
Cervicovaginal Shedding of HIV Type 1 Is Related to Genital Tract Inflammation Independent of Changes in Vaginal Microbiota
Caroline Mitchell,corresponding author1 Jane Hitti,1 Kathleen Paul,1 Kathy Agnew,1 Susan E. Cohn,2,3 Amneris E. Luque,3 and Robert Coombs1
1University of Washington, Seattle, Washington.
2Northwestern University, Chicago, Illinois.
3University of Rochester, Rochester, New York.
corresponding authorCorresponding author.
Address correspondence to: Caroline Mitchell, University of Washington, 325 9th Ave., Box 359865, Seattle, Washington 98104. E-mail:camitch/at/uw.edu
We examined the relationship of proinflammatory vaginal cytokines and secretory leukocyte protease inhibitor (SLPI) with genital HIV-1 shedding after controlling for genital coinfections. Fifty-seven HIV-1-infected women in Seattle, WA (n = 38) and Rochester, NY (n = 19) were followed every 3–4 months for a total of 391 visits. At each visit, plasma and cervicovaginal lavage (CVL) were tested for HIV-1 RNA using qPCR. Vaginal samples were tested for bacterial vaginosis, yeast, hydrogen peroxide-producing Lactobacillus colonization, Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, CMV, and HSV shedding. CVL interleukins (IL)-1β, IL-6, IL-8, and SLPI were measured using ELISA. Linear regression with generalized estimating equations examined effects of cytokine concentrations on CVL HIV-1 RNA, adjusted for plasma HIV RNA, and measured coinfections. CVL IL-1β and IL-8 were significantly associated with CVL HIV-1 RNA. This persisted after adjusting for plasma HIV-1 RNA. Higher levels of IL-1β were associated with higher concentrations of HIV-1 RNA in CVL (β = 0.25, 95% CI 0.09, 0.42), as were higher levels of IL-8 (β = 0.34, 95% CI 0.17, 0.50). Adjusting for the presence of the coinfections described, this relationship was attenuated for IL-1β (β = 0.16; 95% CI –0.01, 0.33) but still significant for IL-8 (β = 0.29; 95% CI 0.13, 0.45). The proinflammatory cytokines IL-1β and IL-8 are associated with higher cervicovaginal HIV-1 RNA concentrations, even after controlling for plasma viral load and vaginal microbial cofactors. This association suggests that there may be additional, noninfectious causes of inflammation that increase cervicovaginal HIV-1 shedding.
Shedding of HIV-1 in genital secretions is an important determinant of the risk of sexual transmission of the virus. Even when plasma viral load is undetectable, transmission is still possible,1,2 likely due to ongoing genital shedding of the virus. Plasma viral load is the primary predictor of HIV-1 shedding in the genital secretions of women,3,4 but localized factors such as cervical, vaginal. and uterine infections also increase the likelihood of viral shedding.5,6 A meta-analysis of over 24 studies of genital infection and HIV-1 shedding showed that Neisseria gonorrhea, Chlamydia trachomatis, yeast vaginitis, cervicitis, and genital ulcers were associated with increased odds of detecting HIV-1 in genital secretions.7 The mechanism for this association is not entirely clear, but many suspect that inflammation related to infections promotes viral transcription from infected cells8 and/or increases vascular permeability. Alternatively, bacterial or viral infections may draw HIV-1-infected T cells to the area,9 increasing viral concentrations and shedding.
Proinflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, and IL-8 are increased in many genital infections1013 and with genital shedding of HIV-1.1416 Vaginal hygiene practices17 and cryotherapy for cervical neoplasia18 have also been associated with genital HIV-1 shedding, which many hypothesize is related to inflammation resulting from trauma to vaginal epithelium. If inflammation is a risk factor for HIV-1 shedding and is present in the absence of infections, treating infections alone may not reduce genital HIV-1 concentrations and risk to sexual partners. In this study, we used the proinflammatory cytokines IL-1β, IL-6, and IL-8 as markers of inflammation and secretory leukocyte protease inhibitor (SLPI) as an antiinflammatory molecule to evaluate the association between HIV-1 shedding and genital inflammation, adjusting for concurrent genital infections.
This was a prospective, observational study of HIV-1-infected women in Seattle, WA (n = 38) and Rochester, NY (n = 19) between 2002 and 2007. Study participants were 18–50 years of age at study entry, were not pregnant or menopausal, had an intact cervix, and had no active genital infections at study entry. There were no entry restrictions with regard to CD4 cell count, plasma viral load, or antiretroviral therapy. The University of Washington and University of Rochester Institutional Review Boards approved the study, and all subjects provided written informed consent.
Participants had four study visits in the first year and three visits per year in subsequent years. Each study visit included a comprehensive face-to-face interview ascertaining demographic information, reproductive and medical history, sexual behavior, and medication use. Plasma was obtained for HIV RNA quantification. A pelvic examination was performed with collection of vaginal swabs. Cervicovaginal lavage (CVL) was collected by lavaging the ectocervix and vaginal walls with 7 ml of 10 mM lithium chloride (LiCl) solution, which was then collected from the vaginal pool, spun at 3000 rpm for 5 min to separate the epithelial cells, and stored at −80°C in 1-ml aliquots. Urine was collected for N. gonorrhea and C. trachomatis detection by nucleic acid amplification (COBAS Amplicor PCR).
Plasma and CVL HIV RNA were quantified by an independently validated real-time polymerase chain reaction (PCR) assay described previously19 with a lower limit of quantification of 30 c/ml. Herpes simplex virus (HSV) serology testing was done by Western blot. CVL was tested for genital shedding of HSV and cytomegalovirus (CMV) using PCR.20,21 CVL was tested for interleukins (IL)-1β, −6, −8, and SLPI using an in-house ELISA with commercial antibodies as previously described10 and values were corrected for dilution using a standard concentration of LiCl per ml of lavage fluid.22 The presence and quantity of Lactobacillus and yeast were ascertained by vaginal culture. Hydrogen peroxide production was ascertained by subculture on tetramethylbenzidine (TMB) agar containing horseradish peroxidase as previously described.23 Bacterial vaginosis (BV) was diagnosed from vaginal Gram stain using Nugent's criteria24; a score of 0–3 was considered normal flora, 4–6 intermediate, and 7–10 positive for BV. A dichotomous variable indicating abnormal vaginal microbiota (Nugent score 4–10) was created for the purposes of analysis. Trichomonas vaginalis was detected by culture using the InPouch system (Hardy Diagnostics, Santa Maria, CA).
Plasma and genital viral loads as well as cytokine concentrations were log10 transformed for the purposes of analysis. We used linear regression with generalized estimating equations and robust standard errors to compare quantities of cytokines between women with and without genital shedding of HIV-1 and to examine effects of log10 cytokine concentrations on log10 CVL HIV-1 RNA, adjusted for log10 plasma HIV RNA, and the presence of abnormal vaginal flora, H2O2+ Lactobacillus colonization, yeast, T. vaginalis, CMV, and HSV shedding. The prevalence of N. gonorrhea and C. trachomatis was so low that these infections were not included in the model.
A total of 57 women enrolled in the study, 38 in Seattle and 19 in Rochester, and completed a total of 391 visits (median visits per person 6, range 1–15). In total, 312 of 391 visits (80%) had complete data for analysis. Participants ranged in age from 23 to 52 years, with a mean of 38 ± 6 years. At enrollment, the mean plasma viral load was 26,218 ± 65,525 c/ml, the CD4 count was 456 ± 285 cells/ml, and the use of antiretroviral therapy was reported by 31/57 (54%). The cohort was primarily white 33/57 (58%), with 13/57 (23%) reporting African-American race and 11/57 (19%) reporting another ethnicity. Just over half, 38/57(55%), had a high school education or less, 10/57(17%) reported some college or technical school, and 9/57 (16%) reported college education or masters degree. Mean gravidity was 6 ± 8 and mean parity was 3 ± 2.
The majority of samples (72%) were collected during the luteal phase of the menstrual cycle. At over half of the visits (52%) women had been sexually active in the past 30 days, and at a third of the visits (30%) women had been sexually active in the past week, but the median time since last intercourse was 13 days (IQR 5, 16). The majority of women (71%) reported sex in the past year with only male partners, while 5 (9%) reported only female partners and 6 (11%) reported both genders. Of 53 women who answered the question at the enrollment visit, 9 (17%) reported never using condoms (4 of whom reported sex only with women in the past year), while 24 (45%) reported always using condoms.
Genital shedding of HIV-1 RNA was detected in CVL at 56/312 (18%) of the visits. The most common genital infection was BV, diagnosed at 89 (29%) of 312 visits, followed by yeast, which was present at 64/312 visits (21%). Trichomoniasis was diagnosed at a small number of visits (15/312, 5%), as were N. gonorrhea and C. trachomatis (4/312, 1%). Although 38/45 (84%) of participants had positive serology for HSV-2, genital shedding of HSV-2 was detected at only 7/312 (2%) of visits. CMV shedding was detected at 10/312 (3%) of visits. H2O2-producing lactobacilli were detected at the majority of visits (193/312; 62%). At 46/312 (15%) visits women had intermediate Nugent scores (4–6). Nonspecific cervicitis, diagnosed by the presence of more than 30 white blood cells per high-powered microscopy field in a cervical swab, was present at 123/312 (39%) of visits.
IL-1β was detectable at 278/312 (90%) visits, IL-6 at 161 (52%), IL-8 at 308 (99%), and SLPI at 232 (74%). In univariate analysis, the presence of abnormal vaginal flora, trichomoniasis, and HSV-2 shedding (Table 1) were associated with higher levels of IL-1β, while the presence of H2O2-producing lactobacilli was associated with lower levels. Yeast vaginitis and HSV-2 shedding were associated with higher levels of IL-8, while the presence of an abnormal Nugent score was associated with lower quantities of SLPI.
Table 1.
Table 1.
Results of Univariate Regression Analysis for Association Between Cytokines Measured in Cervicovaginal Lavage and Presence of Genital Infections at 391 Visits from 57 HIV-1-Infected Womena
Values of IL-1β and IL-8 were significantly different between visits with and without HIV-1 genital shedding detected (Table 2). In regression analysis CVL IL-1β and IL-8 were significantly associated with concentration of CVL HIV-1 RNA and this persisted after adjusting for plasma HIV RNA (Table 3). After adjusting for the presence of H2O2+ Lactobacillus, abnormal Nugent score, yeast, Trichomonas, and CMV or HSV-2 genital shedding, this relationship was attenuated for IL-1β but was still significant for IL-8. Adjusting for sexual activity in the past month, time since sex, time since menses, antiretroviral use, or HSV-2 serology did not change the results of the analysis (data not shown).
Table 2.
Table 2.
Median Cytokine Values at Visits with and without Genital Shedding of HIV-1 RNA (N = 391 Visits from 57 Women)a
Table 3.
Table 3.
Multivariate Analysis of Association Between Cervicovaginal Lavage Cytokines and HIV-1 Genital Sheddinga
In this study we evaluated the association between proinflammatory cytokines IL-1β, IL-6, and IL-8, the antiinflammatory molecule SLPI, and cervicovaginal shedding of HIV-1, controlling for plasma viral load and the presence of genital coinfections. In this analysis, IL-8 is associated with higher cervicovaginal HIV-1 RNA concentrations even after adjusting for the presence of several coinfections and plasma viral load. This association suggests that there may be additional, noninfectious causes of inflammation that increase cervicovaginal HIV-1 shedding.
Genital shedding of HIV-1, while primarily driven by plasma HIV-1 load,3 is likely also mediated by local factors as evidenced by the fact that up to 33% of women with undetectable HIV-1 in plasma continue to shed virus in cervicovaginal secretions.25 Several groups have shown that local, genital markers of inflammation are associated with increased HIV-1 genital shedding.12,15 Anderson et al. showed that the presence of white blood cells in CVL is associated with increased detection of HIV-1 in CVL, even after controlling for plasma viral load,26 but did not control for the presence of genital coinfections. Higher rates of genital shedding of HIV-1 are seen in women with concomitant genital tract infections such as herpes27 or BV.28,29 Treatment of these infections as well as Candida vaginitis and Trichomonas has been shown to decrease HIV-1 shedding.5,30 Many hypothesize that the proinflammatory cytokines associated with infections promote HIV-1 replication and thus increase shedding.
However, noninfectious events are also associated with higher levels of inflammatory markers. Two weeks after cryotherapy of cervical neoplasia, while the cervix was inflamed, Lawn et al. showed that TNF-α and IL-6 were increased, as was HIV-1 RNA in genital secretions.31 Prakash et al. showed that in the 3 days following sexual intercourse, the number of CD4+ T cells in the vaginal epithelium was higher than when women were sampled more than 3 days after intercourse.32 These studies suggest that epithelial trauma—whether from sex, vaginal hygiene practices, or surgical procedures—can cause inflammation and may facilitate HIV-1 shedding. Our results also suggest this; in a model adjusted for the presence of many common genital tract infections, IL-8 (a neutrophil chemoattractant) was independently associated with an increased quantity of HIV-1 shedding.
One of the limitations of our study is that women were seen only every 3–4 months, and proximate behavioral causes of genital inflammation such as frequency and timing of sexual intercourse were measured as an average over that time; thus we have a limited ability to identify what factors are associated with increased genital levels of IL-8. Only 80% of visits had complete data (HIV plasma and CVL values, CVL cytokines, CMV and HSV testing) for analysis, which may create some bias, though there did not seem to be a pattern in which subjects or visits were excluded. It is possible that the association is due to an infectious cause of inflammation that we did not measure, but we tested for the most common causes of vaginitis, genital ulcers, and cervicitis and so the contribution of other infections is likely to be small. HIV-1 shedding was detected at only 18% of visits, which may have limited our power to detect associations but makes the associations that we did detect much more robust.
Genital tract inflammation, and specifically that characterized by the presence of the neutrophil chemoattractant IL-8, is associated with HIV-1 genital shedding independent of the presence of other infections. This suggests that in addition to treatment or sexually transmitted infections, antiinflammatory therapies may be a potential mechanism to decrease HIV-1 shedding and the risk of sexual transmission.
Acknowledgments
Dr. Mitchell is supported by the Women's Reproductive Health Research career Development Award (NICHD). The Women's HIV Interdisciplinary Network study was funded by NIH P01 HD40540.
Author Disclosure Statement
No competing financial interests exist.
1. Chakraborty H. Sen PK. Helms RW, et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. AIDS. 2001;15(5):621–627. [PubMed]
2. Wilson DP. Law MG. Grulich AE. Cooper DA. Kaldor JM. Relation between HIV viral load and infectiousness: A model-based analysis. Lancet. 2008;372(9635):314–320. [PubMed]
3. Kovacs A. Wasserman SS. Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358(9293):1593–1601. [PubMed]
4. Mostad SB. Prevalence and correlates of HIV type 1 shedding in the female genital tract. AIDS Res Hum Retroviruses. 1998;14(Suppl 1):S11–15. [PubMed]
5. Coombs RW. Reichelderfer PS. Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17(4):455–480. [PubMed]
6. Coleman JS. Hitti J. Bukusi EA, et al. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS. 2007;21(6):755–759. [PubMed]
7. Johnson LF. Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: A systematic review and meta-analysis. Sex Transm Dis. 2008;35(11):946–959. [PubMed]
8. Kedzierska K. Crowe SM. Turville S. Cunningham AL. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol. 2003;13(1):39–56. [PubMed]
9. Cohn MA. Frankel SS. Rugpao S, et al. Chronic inflammation with increased human immunodeficiency virus (HIV) RNA expression in the vaginal epithelium of HIV-infected Thai women. J Infect Dis. 2001;184(4):410–417. [PubMed]
10. Mitchell CM. Balkus J. Agnew KJ, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses. 2008;24(5):667–671. [PubMed]
11. Anton G. Rid J. Mylonas I. Friese K. Weissenbacher ER. Evidence of a TH1-shift of local vaginal inflammatory response during bacterial vaginosis. Infection. 2008;36(2):147–152. [PubMed]
12. Spear GT. Zariffard MR. Cohen MH. Sha BE. Vaginal IL-8 levels are positively associated with Candida albicans and inversely with lactobacilli in HIV-infected women. J Reprod Immunol. 2008;78(1):76–79. [PMC free article] [PubMed]
13. Hedges SR. Barrientes F. Desmond RA. Schwebke JR. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis. 2006;193(4):556–562. [PubMed]
14. McGowan I. Elliott J. Fuerst M, et al. Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation. J Acquir Immune Defic Syndr. 2004;37(2):1228–1236. [PubMed]
15. Cummins JE. Christensen L. Lennox JL, et al. Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses. 2006;22(8):788–795. [PubMed]
16. Spear GT. Zariffard MR. Chen HY, et al. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses. 2008;24(7):973–976. [PMC free article] [PubMed]
17. Clark RA. Theall KP. Amedee AM. Kissinger PJ. Frequent douching and clinical outcomes among HIV-infected women. Sex Transm Dis. 2007;34(12):985–990. [PubMed]
18. Wright TC., Jr. Subbarao S. Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001;184(3):279–285. [PubMed]
19. Zuckerman RA. Lucchetti A. Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: A randomized, double-blind, placebo-controlled crossover trial. J Infect Dis. 2007;196(10):1500–1508. [PubMed]
20. Mostad SB. Kreiss JK. Ryncarz AJ, et al. Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol. 1999;59(4):469–473. [PubMed]
21. Corey L. Huang ML. Selke S. Wald A. Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. J Med Virol. 2005;76(3):350–355. [PubMed]
22. Mohamed AS. Becquart P. Hocini H. Metais P. Kazatchkine M. Belec L. Dilution assessment of cervicovaginal secretions collected by vaginal washing to evaluate mucosal shedding of free human immunodeficiency virus. Clin Diagn Lab Immunol. 1997;4(5):624–626. [PMC free article] [PubMed]
23. Eschenbach DA. Davick PR. Williams BL, et al. Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol. 1989;27(2):251–256. [PMC free article] [PubMed]
24. Nugent RP. Krohn MA. Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301. [PMC free article] [PubMed]
25. Neely MN. Benning L. Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44(1):38–42. [PMC free article] [PubMed]
26. Anderson BL. Wang CC. Delong AK, et al. Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis. 2008;47(9):1216–1221. [PMC free article] [PubMed]
27. Ouedraogo A. Nagot N. Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: A randomized controlled trial. AIDS. 2006;20(18):2305–2313. [PubMed]
28. Cu-Uvin S. Hogan JW. Caliendo AM. Harwell J. Mayer KH. Carpenter CC. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis. 2001;33(6):894–896. [PubMed]
29. Sha BE. Zariffard MR. Wang QJ, et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis. 2005;191(1):25–32. [PubMed]
30. Wang CC. McClelland RS. Reilly M, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis. 2001;183(7):1017–1022. [PubMed]
31. Lawn SD. Subbarao S. Wright TC, Jr., et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis. 2000;181(6):1950–1956. [PubMed]
32. Prakash M. Patterson S. Gotch F. Kapembwa MS. Recruitment of CD4 T lymphocytes and macrophages into the cervical epithelium of women after coitus. Am J Obstet Gynecol. 2003;188(2):376–381. [PubMed]
Articles from AIDS Research and Human Retroviruses are provided here courtesy of
Mary Ann Liebert, Inc.